In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
A meta-analysis of randomized controlled trials presented at the American College of Cardiology’s Annual Scientific Session suggests RNA therapeutics reduce mortality and cardiac failure risk in...
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
A real-world analysis found that mRNA SARS-CoV-2 vaccination was associated with lower 3-year mortality after CAR T-cell therapy in patients with hematologic malignancies.
Updated 5-year data from KEYNOTE-942 showed that intismeran autogene plus pembrolizumab maintained durable recurrence-free and distant metastasis-free survival benefits in patients with high-risk resected...
